India’s biotechnology landscape is undergoing a transformative leap. Bolstered by inclusive policies like BioE3 (for economy, environment, and employment) and Bio-RIDE, the bioeconomy has exploded from $10 billion in 2014 to nearly $166 billion in 2024 on track to reach $300 billion by 2030.
The catalyst for this growth? A surge in innovation-led startups from around 50 a decade ago to nearly 9,000–11,000 today backed by institutional support from DBT, BIRAC, and PLI schemes.
India is now shifting from generics toward biosimilars, monoclonal antibodies, cell & gene therapies, mRNA platforms, and domestically-developed CAR-T treatments. With 49% of the sector driven by biopharma valued at $39 billion in 2021 this evolution is reshaping our global role.
Post a comment
Jyotiraditya Scindia reveals govt’s cyber action plan!
Communications Minister Scindia outlined five key anti-cybercrime initiatives, including new reporting systems, coordination centres, and...
NISAR Launch today : ISRO’s satellite to map earth like...
On July 30, 2025, NASA‑ISRO’s NISAR mission lifts off ushering in dual‑frequency radar technology to...
Airports in UK freeze! Flights restricted now
A technical glitch at NATS control centre grounded outbound flights from Heathrow, Gatwick, Edinburgh and...
Tired of delays? 'Delhi Mitra’ App is here to simplify...
The Delhi Cabinet has approved the Delhi Mitra app, enabling citizens to register complaints digitally...
